An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE‐ε4 in Alzheimer’s disease
JIANG Y, Zhou X, Wong H, Li O, Ip F, Chau V, Lau S, Wu W, Wong D, Seo H, Fu W, Lai N, Chen Y, Chen Y, Tong E, Mok V, Kwok T, Mok K, Shoai M, Lehallier B, Moran‐Losada P, O’Brien E, Porter T, Laws S, Hardy J, Wyss‐Coray T, Masters C, Fu A, Ip N, Initiative A. An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE‐ε4 in Alzheimer’s disease. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.064428.Peer-Reviewed Original ResearchGenome-wide association studiesGenetic regulationAlzheimer's diseaseGenome-wide association study analysisGenetic variantsPathogenesis of Alzheimer's diseaseAD risk genesDisease-causing roleAPOE-e4 carriersAssociation studiesGenetic variationAmyloid-betaRisk genesMicroglial clearanceBrains of patientsBackground genetic factorsAD therapySevere neurodegenerationMicroglial dysfunctionAb accumulationMicroglial functionDecoy receptorGenetic factorsAPOE-e4IL1RL1
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply